MOXIFLOXACIN Drug Patent Profile
✉ Email this page to a colleague
When do Moxifloxacin patents expire, and when can generic versions of Moxifloxacin launch?
Moxifloxacin is a drug marketed by Alembic, Apotex, Epic Pharma Llc, Eugia Pharma, Fdc Ltd, Gland, Lupin, Mankind Pharma, Pharmobedient, Regcon Holdings, Somerset Theraps Llc, Upsher Smith Labs, Fresenius Kabi Usa, Aurobindo Pharma Ltd, Chartwell Rx, Crossmedika Sa, Dr Reddys, Hetero Labs Ltd V, Macleods Pharms Ltd, MSN, Natco, Sunshine, Teva Pharms Usa, Torrent, and Mylan Labs Ltd. and is included in twenty-six NDAs.
The generic ingredient in MOXIFLOXACIN is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Moxifloxacin
A generic version of MOXIFLOXACIN was approved as moxifloxacin hydrochloride by TEVA PHARMS USA on February 18th, 2014.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MOXIFLOXACIN?
- What are the global sales for MOXIFLOXACIN?
- What is Average Wholesale Price for MOXIFLOXACIN?
Summary for MOXIFLOXACIN
| US Patents: | 0 |
| Applicants: | 25 |
| NDAs: | 26 |
| Drug Prices: | Drug price information for MOXIFLOXACIN |
| What excipients (inactive ingredients) are in MOXIFLOXACIN? | MOXIFLOXACIN excipients list |
| DailyMed Link: | MOXIFLOXACIN at DailyMed |
